Cytokinetics CYTK 深 沪
等待开盘 10-07 09:30:00 美东时间
61.35
-1.350
-2.15%
华盛通- 最 高79.875
- 今 开62.20
- 成交量 315.08万股
- 最 低 60.68
- 昨 收 62.70
- 总市值 525.48万
- 52周最高 88.31
- 市盈率 静 --
- 换手率 3678.61%
- 52周最低 54.30
- 委 比 63.57%
- 总股本 8.57万
- 历史最高 110.25
- 量 比 1.14
- 振 幅 30.61%
- 历史最低 0.57
- 每 手 1
- 风险率 7.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
09-26 04:19
New AI ETF Bets on Healthcare's $9 Trillion Opportunity
Tema's new Healthcare AI ETF (HLTH), targets AI-powered drug discovery, diagnostics, robotics and patient care.
07-25 03:08
8 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
07-07 01:35
Preview: Cytokinetics's Earnings
Cytokinetics (NASDAQ:CYTK) is set to give its latest quarterly earnings report ...
02-24 00:02
Cytokinetics Wins FDA Nod For Heart Drug Myqorzo
FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to launch in 2026.
2025-12-23 00:23
Market-Moving News for December 22nd
CYTK: 8% | Cytokinetics shares were trading higher after the company announced that the FDA approved MYQORZO, 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic
2025-12-22 20:38
Cytokinetics将发行可转换优先票据筹集最多5.5亿美元
周三盘前，生物制药公司Cytokinetics（CYTK）上涨0.6%，此前该公司宣布，计划通过发行2031年到期的可转换优先票据筹集最多5.5亿美元资金。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-09-17 20:42
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted stock options and RSUs to 11 new employees as an inducement to employment. The company is focused on developing cardiovascular therapies, including aficamten, omeccamiv mecarbil, and CK-586, for various heart conditions.
2025-06-17 20:00
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
Cytokinetics公司宣布启动2025年度企业捐赠计划，计划向符合条件的美国非营利组织提供慈善捐赠，支持心血管疾病领域的健康公平、科学教育中的多样性以及为本地和高风险社区提供的基本服务。申请截止日期为2025年8月4日，申请链接已提供。
2025-06-10 11:30
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
Cytek Biosciences unveiled the Cytek Aurora™ Evo system, a next-generation full spectrum flow cytometer offering improved sample throughput, automation capabilities, and enhanced detection of small particles. Building on the trusted performance of the Cytek Aurora system, the Aurora Evo empowers researchers with high-speed workflows and consistent data quality to accelerate discoveries in cell analysis.
2025-05-29 21:00
